Soluble TNFα blockade enhances trastuzumab deruxtecan antitumor effect in HER2-positive breast cancer model

被引：0
|
作者：
Bruni, Sofia
Mauro, Florencia
Proietti, Cecilia
Cordo-Russo, Rosalia
Schillaci, Roxana
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-11-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-12
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [32] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679
  • [33] Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
    Nakajima, Hiromichi
    Harano, Kenichi
    Nakai, Tokiko
    Kusuhara, Shota
    Nakao, Takehiro
    Funasaka, Chikako
    Kondoh, Chihiro
    Matsubara, Nobuaki
    Naito, Yoichi
    Hosono, Ako
    Mitsunaga, Shuichi
    Ishii, Genichiro
    Mukohara, Toru
    BREAST, 2022, 61 : 136 - 144
  • [34] Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors
    Yin, Ophelia
    Xiong, Yuan
    Endo, Seiko
    Yoshihara, Kazutaka
    Garimella, Tushar
    AbuTarif, Malaz
    Wada, Russ
    LaCreta, Frank
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (05) : 1314 - 1325
  • [35] Effectiveness of trastuzumab deruxtecan rechallenge in a patient with HER2-positive metastatic breast cancer: a case report
    Tanaka, Yuko
    Ikeda, Naoya
    Niho, Seiji
    Ishida, Kazuyuki
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2024, 13 (04): : 353 - 359
  • [36] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Mortimer, Joanne
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07): : 662 - 663
  • [37] Trastuzumab (herceptin) and HER2-positive breast cancer
    Murray, S
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (01) : 36 - 37
  • [38] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    LANCET, 2005, 366 (9486): : 634 - 634
  • [39] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [40] HER2-Positive Breast Cancer: Beyond Trastuzumab
    Murphy, Conleth G.
    Fornier, Monica
    ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
12345